TRIMTECH Therapeutics

Trimtech Therapeutics is developing selective small molecule degraders of toxic protein aggregates for treatment of neurodegenerative and peripheral diseases, while leaving functional monomers untouched. The company’s proprietary degrader technology leverages TRIM21 biology as pioneered by the company’s founders Dr Leo James and Dr Will McEwan from the University of Cambridge.

Trimtech is headquartered in Cambridge, UK and backed by an experienced life science investor syndicate, including M Ventures, SV Health Investors’ Dementia Discovery Fund, Cambridge Innovation Capital, Pfizer Ventures, MP Healthcare Venture Management (MPH), Eli Lilly and Company, Cambridge Enterprise Ventures, and Start Codon